Gastroenterology

During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Between 2002-2019, NASH is the leading liver indication for women without HCC.

New recommendations support the use of probiotics for preterm and low birthweight infants to prevent mortality and necrotizing enterocolitis.

In recent years, ustekinumab and tofacitinib have both been effective in treating ulcerative colitis.

Researchers are continuing to learn how the COVID-19 virus will effect patients with inflammatory bowel disease.

In an international survey, investigators discover women are more likely to suffer from a FGID than men.

The findings can lead physicians to stop prescribing the drug.

Investigators estimate 40-50% of proton pump inhibitor users are using inappropriately.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

Obstructive sleep apnea can be linked to the development of non-alcoholic fatty liver disease.

Patients with more severe viral infections had higher rates of gastrointestinal symptoms.

Both inflammatory bowel disease and celiac disease share similar risk factors.

Investigators find bowel wall abnormalities in 31% of CT scans conducted in a 412 patient study.

Individuals who commonly eat popcorn and drink milk have smaller odds of developing IBD.

A majority NASH patients receiving 0.4 mg of subcutaneous semaglutide has disease resolution following the 72-week phase 2 study.

In a new study, investigators discover fewer adverse events in patients taking 1 × 109 non-viable B bifidum HI-MIMBb75 cells than for patients taking a placebo.

The new recommendations call for enhanced symptom monitoring for patients experiencing gastrointestinal issues.

The adjusted estimate of the burden of hospitalizations related to C. diff infections decreased by 24% between 2011-2017.

In a phase 3 clinical trial, endoscopic endpoints were similar between treatment and placebo groups.

New guidelines suggest patients with moderate to severe ulcerative colitis should be treated with infliximab, tofacitinib, and ustekinumab.

The most common reason IBS patients discontinue treatment is a loss of prescription drug coverage.

Dr. David Rubin discusses what IBD patients can do if they are asked to stop immunosuppressant treatment because of COVID-19.

David T. Rubin, MD, discusses some of the reccomendations for treating patients with IBD during the pandemic.

Within 5 days of a colonoscopy, individuals have higher levels of shock than the general population, new findings show.